Trading & Distributors

Genpharmasec Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 27 filings·Updated 13 Aug 2026
Showing 10 of 27 filings.
13 Aug 20262 filings
Company UpdatePress Release / Media Release

Genpharmasec Limited signs nonexclusive Supper Stockist agreement with Amneal Healthcare Private Limited

Agreement with Amneal Healthcare

  • Genpharmasec entered into a nonexclusive Supper Stockist agreement with Amneal Healthcare Private Limited.
  • AHPL commits to minimum annual sales of approximately INR 75 Crores per calendar year.
Filed 16:59View Source
Company UpdateNewspaper Publication

Newspaper Publication of Unaudited Financial Results for the quarter ended 30th June, 2026.

Filed 10:56View Source
11 Aug 20262 filings
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Rights Issue proceeds show no deviation in use of funds

Fund-raising details

  • Mode of fund raising: Rights Issue.
  • Monitoring agency: Not Applicable.

Utilisation status

  • No deviation or variation in use of funds raised.
  • Funds utilised per original allocations; balance unutilised.
  • Audit Committee comments: No comments.
  • Status: Partly utilised.

Object allocations

  • Original allocations total the raised proceeds; no deviation detected.
  • No material deviation observed at the object level.
Filed 16:21View Source
Board MeetingOutcome of Board Meeting

Genpharmasec approves unaudited standalone and consolidated financial results for quarter ended June 30, 2026

Financial results approved

  • Un-audited standalone and consolidated financial results for quarter ended June 30, 2026 approved; Limited Review Reports attached.

Audit committee and review

  • Results reviewed by the Audit Committee prior to approval.

Regulatory/compliance notes

  • Interim results prepared in accordance with Ind AS 34; Regulation 33 LR reports issued.

Board meeting details

  • Board meeting held August 11, 2026, 03:00–03:50 PM.

Subsidiaries / Annexure

  • Annexure I lists three subsidiaries: Clinigenome India Private Limited; Genpharmasec Middle East DMCC; Derren Healthcare Private Limited.

Auditor remarks

  • Independent reviews provide moderate assurance; no audit opinion issued for interim results.

Scope of interim results

  • Unaudited results for quarter ended June 30, 2026; March 31, 2026 comparatives audited.
Filed 16:02View Source
7 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) certificate confirms no demat requests; securities listed; depository records updated

Dematerialisation status

  • No dematerialisation/rematerialisation requests were received in the quarter ended 30 June 2026.
  • The securities comprised in the certificates have been listed on the stock exchanges.
Filed 11:17View Source
23 May 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March, 2026.

Filed 10:53View Source
13 May 20261 filing
Board Meeting

Genpharmasec Ltd - 531592 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday, 21St May, 2026.

Meeting Details

  • Board meeting on Thursday, 21 May 2026, at the registered office.
  • Meeting date disclosed as 21 May 2026; time not specified.

Key Agenda Items

  • Approve audited standalone and consolidated financial results for quarter and year ended 31 March 2026.
  • Take on record the auditor’s report on those audited financial results.

Other Notes

  • Trading window closed from 1 April 2026 until 48 hours after results declaration.
Filed 11:37View Source
14 Apr 20261 filing
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Filed 15:45View Source
8 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended March 31, 2026.

Filed 10:54View Source
26 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of closure of Trading window.

Filed 12:24View Source
Showing 10 of 27 filings